# NeoGenomics, Inc. (NEO): MoatMap facts

As of 29 Oct 2026. Research data, not investment advice.

As of 29 Oct 2026, MoatMap's StockRank for NeoGenomics, Inc. (NEO) is 49/100, ranked against 24,000+ stocks in 35 markets (Quality 41, Value 26, Momentum 76, each scored against its sector).

- StockRank: 49/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 41, Value 26, Momentum 76: each a 0-100 percentile within Healthcare.
- Position: #13,369 overall, #1,204 in Healthcare.
- Listing: United States, NCM; Healthcare / Diagnostics & Research.
- Last close: 17.99 USD on 28 Oct 2026.
- Insider filings, last 180 days: directors sold USD 440K.
- Buybacks, last 180 days: the company bought back USD 25.0M on 1 day.

Source: https://moatmap.ai/stock/NEO
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker